Edition:
India

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

40.68USD
15 Feb 2019
Change (% chg)

$1.00 (+2.52%)
Prev Close
$39.68
Open
$39.76
Day's High
$40.92
Day's Low
$39.45
Volume
193,263
Avg. Vol
176,848
52-wk High
$54.92
52-wk Low
$26.98

Latest Key Developments (Source: Significant Developments)

Pacira Expands Exparel Manufacturing Capacity
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA EXPANDS EXPAREL MANUFACTURING CAPACITY TO MEET GROWING DEMAND.PACIRA PHARMACEUTICALS - COMMERCIAL PRODUCTION OF EXPAREL UNDERWAY AT SWINDON, UK CREATED UNDER PARTNERSHIP WITH THERMO FISHER SCIENTIFIC PHARMA.PACIRA - DEVELOPING 2ND DEDICATED SUITE EXPECTED TO ENABLE ANOTHER DOUBLING OF EXPAREL MANUFACTURING CAPACITY IN ABOUT 2 YRS UNDER PARTNERSHIP.  Full Article

Pacora Pharma Study Shows Reductions In Opioid Consumption In Cesarean Section Patients
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Pacira Pharmaceuticals Inc ::EXPAREL ACHIEVES STATISTICALLY SIGNIFICANT REDUCTIONS IN OPIOID CONSUMPTION AND PAIN SCORES IN CESAREAN SECTION PATIENTS.PACIRA PHARMACEUTICALS INC - STUDY ACHIEVED ITS PRIMARY ENDPOINT.PACIRA PHARMACEUTICALS INC - PHASE 4 STUDY OF EXPAREL ALSO ACHIEVED STATISTICAL SIGNIFICANCE FOR REDUCTION IN PAIN INTENSITY SCORES THROUGH 72 HOURS.  Full Article

Pacira Reports Preliminary 2018 Net Exparel Sales Of $331 Mln
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA REPORTS PRELIMINARY 2018 NET EXPAREL® SALES OF $331 MILLION.PACIRA PHARMACEUTICALS INC - REPORTED PRELIMINARY UNAUDITED EXPAREL NET PRODUCT SALES OF $94 MILLION FOR Q4.PACIRA PHARMACEUTICALS INC - REPORTED PRELIMINARY UNAUDITED EXPAREL NET PRODUCT SALES OF $331 MILLION FOR FY 2018.  Full Article

Consonance Capital Reports 8.9 Pct Stake In Pacira Pharmaceuticals As Of Oct 16
Tuesday, 23 Oct 2018 

Oct 22 (Reuters) - Consonance Capital Management Lp: :CONSONANCE CAPITAL MANAGEMENT LP REPORTS 8.9 PERCENT STAKE IN PACIRA PHARMACEUTICALS AS OF OCTOBER 16, 2018 - SEC FILING.CONSONANCE CAPITAL MANAGEMENT LP - BELIEVE THAT PACIRA PHARMACEUTICALS' COMMON STOCK IS UNDERVALUED & IS AN ATTRACTIVE INVESTMENT.  Full Article

Pacira Pharmaceuticals Sees Q2 Net Exparel Sales Of $80.4 Mln
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA REPORTS PRELIMINARY NET EXPAREL® SALES OF $80.4 MILLION FOR SECOND QUARTER OF 2018.SEES Q2 NET EXPAREL SALES OF $80.4 MILLION.CONFIDENT IN NEAR- AND LONG-TERM GROWTH OUTLOOK FOR EXPAREL.  Full Article

Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION.Q4 REVENUE $79.1 MILLION VERSUS I/B/E/S VIEW $79.4 MILLION.  Full Article

Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals Inc reports third quarter 2017 financial results.Q3 non-gaap earnings per share $0.11.Q3 gaap loss per share $0.19.Q3 revenue $67.3 million versus I/B/E/S view $69.6 million.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Pacira Pharmaceuticals Inc - ‍Full-year exparel net product sales guidance revised to $280 to $285 million​.Pacira Pharmaceuticals Inc - ‍Updating its full year 2017 sales guidance and reiterating its remaining financial guidance​.FY2017 revenue view $291.8 million -- Thomson Reuters I/B/E/S.  Full Article

Pacira Pharma to invest up to $25 million in Tela Bio
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Pacira Pharmaceuticals Inc :Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​.Under terms of agreement, Pacira will make an initial investment of $15 million​.Under terms of agreement, Pacira is entitled to one seat on Tela Bio board of directors​.Agreement also includes a standstill provision precluding a change of control in Tela Bio for at least 12 months​.  Full Article

Pacira Pharmaceuticals announces FDA acceptance of SNDA
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia.Pacira Pharmaceuticals Inc - ‍expected action date by FDA under Prescription Drug User Fee Act (PDUFA) is April 6, 2018​.  Full Article